Almost 40% of LCNECs have molecular alterations often identified in non-small cell lung cancer (STK11, and KEAP1 mutations) with high expression of ASCL1 and neuroendocrine markers (defined as type I LCNEC) [23,24]. This evidence concerns the gene KEAP1 and large cell neuroendocrine carcinoma.